Neurocrine Biosciences
NBIX
600 hedge funds and large institutions have $12.9B invested in Neurocrine Biosciences in 2024 Q4 according to their latest regulatory filings, with 113 funds opening new positions, 213 increasing their positions, 212 reducing their positions, and 74 closing their positions.
53% more first-time investments, than exits
New positions opened: 113 | Existing positions closed: 74
30% more funds holding in top 10
Funds holding in top 10: 10 → 13 (+3)
20% more capital invested
Capital invested by funds: $10.7B → $12.9B (+$2.17B)
5% more funds holding
Funds holding: 574 → 600 (+26)
1.14% more ownership
Funds ownership: 92.28% → 93.41% (+1.1%)
9% more call options, than puts
Call options by funds: $48M | Put options by funds: $44.2M
0% more repeat investments, than reductions
Existing positions increased: 213 | Existing positions reduced: 212
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$214M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$95.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$91.4M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$88.1M |
| 5 |
AC
Armistice Capital
New York
|
+$87.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$76.5M |
| 2 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$67.1M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$56.5M |
| 4 |
DM
Deerfield Management
New York
|
-$56.2M |
| 5 |
Amundi
Paris,
France
|
-$48.8M |
NBIX Hedge Fund Activity: Q4 2024 in Review
600 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2024, worth a combined $12.9B — up 20% from $10.7B a quarter earlier.
Buyers outnumbered sellers: 113 funds opened new NBIX positions and 74 closed out — a net gain of 39 holders — while 213 added to existing stakes and 212 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $214M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $76.5M.
- 600 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2024, up from 574 in Q3 2024.
- Funds reported $12.9B of Neurocrine Biosciences stock for Q4 2024, up 20% quarter-over-quarter.
- 113 funds opened new Neurocrine Biosciences positions in Q4 2024 and 74 closed out, a net change of +39 holders.
- The largest Neurocrine Biosciences buyer in Q4 2024 was Dodge & Cox, an estimated $214M added.
- The largest Neurocrine Biosciences seller in Q4 2024 was Qube Research & Technologies (QRT), an estimated $76.5M sold.
Based on aggregated 13F filings for Q4 2024.